Unibest

Pharmaceutical intermediates

Ponatinib Hydrochloride Intermediates

2 pharmaceutical intermediates for Ponatinib Hydrochloride. Indication: Acute lymphoblastic leukemia; Chronic myeloid leukemia.

提交项目All intermediates

About Ponatinib Hydrochloride

Originator
Ariad Pharmaceuticals Inc
Indication
Acute lymphoblastic leukemia; Chronic myeloid leukemia
Approved Date
12/18/2020
DS/DP
12/22/2026

Available intermediates

2 intermediates currently listed for Ponatinib Hydrochloride. Request specifications, documentation or a quotation for any item below.

Ponatinib Hydrochloride intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
4-(4-Methylpiperazin-1-ylmethyl)-3-trifluoromethylaniline694499-26-8//
3-Ethynylimidazolo[1,2 -b]pyridazine943320-61-4//

Other programs under P

PacritinibPalbociclibParecoxib sodiumParicalcitolPaxlovidPazopanib HydrochloridePeficitinib HydrobromidePemafibrate

Building toward Ponatinib Hydrochloride?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →